Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: • Less than…
RELATED ARTICLES
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
